Cell changes drive breast cancer relapse
Researchers identify features of residual breast cancer cells that suggest new approaches for preventing relapse
“Our results suggest that residual cells retain an “oncogenic memory” that could be exploited to develop drugs against breast cancer recurrence,” says Martin Jechlinger, who led the research at EMBL.
Thanks to improvements in primary care, more and more breast cancer patients survive the initial tumour. Although treatments like chemotherapy and mastectomies aim to eliminate all of a patient’s tumour cells, breast cancer cells that survive these initial therapies often reinitiate growth, causing a relapse further down the line. These residual cells are difficult to identify and analyse because, until they relapse, they look and act as normal cells. This means breast cancer relapse has remained largely unexplored, and makes it difficult to predict if and when a patient will experience relapse.
Residual cells have a chemical signature
“We found that residual cells have molecular traits that clearly distinguish them from normal breast tissue, and seem to cause relapse,” Jechlinger explains. “When we treated those features in mice, their tumours were less likely to recur.”
Jechlinger and colleagues found that, compared to healthy cells, residual cancer cells have altered lipid metabolism. This contributes to maintaining high levels of “reactive oxygen species” — chemically reactive molecules that are known to damage DNA. The scientists think that this damage triggers the relapse.
The team then compared the findings from the mouse model to samples from breast cancer patients, thanks to collaborators at the European Institute of Oncology in Milan, Italy, and the National Centre for Tumour Diseases in Heidelberg, Germany. The two sets of results were consistent, which suggests they could be useful to understand and treat breast cancer recurrence in humans.
“Every patient is different and every story is unique, but our results suggest that lipid metabolism is an exciting therapeutic target to reduce breast cancer recurrence,” says Kristina Havas, who carried out much of the research in Jechlinger’s lab at EMBL.
EMBL is Europe's flagship laboratory for the life sciences. We are an intergovernmental organisation established in 1974 and are supported by over 20 member states.
EMBL performs fundamental research in molecular biology, studying the story of life. We offer services to the scientific community; train the next generation of scientists and strive to integrate the life sciences across Europe.
We are international, innovative and interdisciplinary. We are more than 1600 people, from over 80 countries, operating across five sites in Grenoble (France), Hamburg (Germany), Heidelberg (Germany), Hinxton (UK) and Monterotondo (Italy). Our scientists work in independent groups and conduct research and offer services in all areas of molecular biology.
Our research drives the development of new technology and methods in the life sciences. We work to transfer this knowledge for the benefit of society.